Delivery Order SPE2DB22D1041-SPE2DB25FUBM4
Award Date 8/15/25
Potential Completion Date 8/18/25
Potential Value $28K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $5,686.91 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors with a completion date of September 2, 2025. This competitively awarded contract, issued on August 29, 2025, utilizes a firm fixed price structure with no set-aside designation. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. Zepbound is a...
- The Defense Logistics Agency awarded a Delivery Order valued at $10,288.27 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. This competitively awarded contract, utilizing firm fixed pricing with no set-aside designation, calls for delivery by August 8, 2025, to the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication commonly prescribed for weight management and metabolic health support....
- The Defense Logistics Agency awarded a delivery order valued at $5,138.94 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitive award, with no set-aside designation, utilizes firm fixed pricing and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist medication used for weight management, represents...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a delivery order valued at $16,836.29 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on July 18, 2025, with completion scheduled for July 21, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist medication used for weight management, represents part of the broader...
- The Defense Logistics Agency awarded a $13,150.18 delivery order to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pen injectors on September 9, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management, reflecting the federal...
- The Defense Logistics Agency awarded a delivery order valued at $12,329.41 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication commonly used for weight...
- The Defense Logistics Agency awarded a delivery order valued at $1,143.87 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 7, 2025. This firm fixed-price delivery order, which is a child contract under AmerisourceBergen's larger pharmaceutical supply agreement, represents a competitive award with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August...
- The Defense Logistics Agency awarded a delivery order valued at $3,386.63 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used in diabetes and weight management treatment, representing a specialized pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $26,560.38 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on September 8, 2025, with an ultimate completion date of September 9, 2025. This firm fixed price delivery order carries no set-aside designation and was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. Zepbound is a tirzepatide-based...